ArticleCancer medicine2022
Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors.
Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- The load of hepatitis B virus reduces the immune checkpoint inhibitors efficiency in hepatocellular carcinoma patients.Frontiers in immunology · 2024Pooled it
- IntratumoralACS omega · 2026Article
- NK-cell-derived exosomes exert antitumor potency via miR-140/XYLT1/HSPG2 axis.Cellular & molecular biology letters · 2026Article
- An increase in splenic volume after first-line immunotherapy is associated with worse PFS in patients with metastatic renal cell carcinoma.The oncologist · 2026Article
- A method for magnetic resonance splenomegaly image segmentation based on large-kernel multi-scale attention mechanism.Scientific reports · 2026Article
- Association between splenic volume changes and prognosis in advanced gastric cancer patients receiving chemotherapy combined with immunotherapy.Frontiers in oncology · 2026Article
- TGFBR2 coordinates the endometrial response to estrogen, regulating endometrial hyperplasia and fertility.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Does volume change of the spleen correlate with the therapy response in uveal melanoma patients with liver metastases undergoing hepatic artery infusion chemotherapy?Radiology and oncology · 2025Article
- In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled withEJNMMI radiopharmacy and chemistry · 2025Article
- Erythroid progenitor cell-mediated spleen-tumor interaction deteriorates cancer immunity.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Spleen Volume Dynamics and Survival Outcomes in HCC Patients Undergoing Immune Checkpoint Inhibitors: A Retrospective Analysis.Journal of hepatocellular carcinoma · 2025Article
- Immunotherapy combined with targeted therapy and transcatheter arterial chemoembolization: a promising approach for advanced liver cancer.American journal of translational research · 2025Article
- Splenic volume as a predictor of survival in cancer patients treated with immune checkpoint inhibitors.Frontiers in immunology · 2025Article
- The augmentation of cytotoxic immune cell functionality through physical exertion bolsters the potency of chemotherapy in models of mammary carcinoma.Cancer medicine · 2024Article
- Lactylation signature identifies liver fibrosis phenotypes and traces fibrotic progression to hepatocellular carcinoma.Frontiers in immunology · 2024Article
- Preoperative splenic area as a prognostic biomarker of early-stage non-small cell lung cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Efficacy and safety of different PD-1 inhibitors in combination with lenvatinib in the treatment of unresectable primary liver cancer: a multicentre retrospective study.Discover oncology · 2023Article
- Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response.Molecular therapy oncolytics · 2023Article
- Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Splenomegaly in predicting the survival of patients with advanced primary liver cancer treated with immune checkpoint inhibitors.Cancer medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsImmune checkpoint inhibitors (ICIs) play an increasingly important role in the treatment of primary liver cancer (PLC). Some patients with PLC experience symptoms of splenomegaly. Splenomegaly may affect the efficacy of ICIs due to an imbalance of the immune microenvironment. Currently, there is a lack of evidence on the relationship between splenomegaly and prognosis in patients with PLC treated with ICIs. This study analyzed the relationship between splenomegaly and prognosis in patients with PLC treated with ICIs.
methodsIn this retrospective cohort study of 161 patients with PLC treated with ICIs, splenomegaly was diagnosed using computed tomography or magnetic resonance imaging and the impact of splenomegaly on patient survival was analyzed.
resultsThrough univariate and multivariate Cox regression analyses, we determined that splenomegaly was associated with shortened overall survival (p = 0.002) and progression-free survival (p = 0.013) in patients with PLC treated with ICIs. Kaplan-Meier analysis further validated our results. The overall survival and progression-free survival of patients with splenomegaly were significantly shorter than those of patients without splenomegaly (p < 0.01 and p = 0.02, respectively).
conclusionsWe concluded that splenomegaly was a predictor of prognosis in patients with PLC treated with ICIs. This is the first study to report this important finding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.